Rossella Ribolla
About
Rossella Ribolla is a scholar working on Hematology, Molecular Biology and Oncology.
According to data from OpenAlex, Rossella Ribolla has authored 21 papers receiving a total of 183 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Hematology, 8 papers in Molecular Biology and 6 papers in Oncology. Recurrent topics in Rossella Ribolla's work include Multiple Myeloma Research and Treatments (15 papers), Acute Myeloid Leukemia Research (4 papers) and Lymphoma Diagnosis and Treatment (4 papers). Rossella Ribolla is often cited by papers focused on Multiple Myeloma Research and Treatments (15 papers), Acute Myeloid Leukemia Research (4 papers) and Lymphoma Diagnosis and Treatment (4 papers). Rossella Ribolla collaborates with scholars based in Italy, Netherlands and United States. Rossella Ribolla's co-authors include Giuseppe Rossi, Angelo Belotti, Valeria Cancelli, Marco Chiarini, Chiara Cattaneo, Mara Gavazzoni, Marco Metra, Enrico Vizzardi, Riccardo Raddino and Alessandra Tucci and has published in prestigious journals such as Journal of Clinical Oncology, Blood and European Journal of Pharmacology.
In The Last Decade
Rossella Ribolla
18 papers receiving 180 citations
Peers
Rossella Ribolla
Hans‐Günter Derigs Germany
Dixil Francis United States
Jennie B. Feliu United States
Katarina Uttervall Sweden
Maria López‐Pavía Spain
Shlomzion Aumann Israel
Erika Morsia Italy
Kayleen Bailey United States
Adrienne Briggs United States
Lionel Adès France
Citations per year, relative to Rossella Ribolla Rossella Ribolla (= 1×)
peers
Hans‐Günter Derigs
Countries citing papers authored by Rossella Ribolla
Since
Specialization
Citations
This map shows the geographic impact of Rossella Ribolla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rossella Ribolla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rossella Ribolla more than expected).
Fields of papers citing papers by Rossella Ribolla
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Rossella Ribolla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rossella Ribolla. The network helps show where Rossella Ribolla may publish in the future.
Co-authorship network of co-authors of Rossella Ribolla
This figure shows the co-authorship network connecting the top 25 collaborators of Rossella Ribolla. A scholar is included among the top collaborators of Rossella Ribolla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rossella Ribolla. Rossella Ribolla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Belotti, Angelo, Barbara Frittoli, Rossella Ribolla, et al.. (2025). Early identification of functional high-risk multiple myeloma patients after transplant: the predictive power of fat fraction and Response Assessment Category score in diffusion-weighted whole-body magnetic resonance imaging. Haematologica. 110(9). 2151–2159.
2.
Belotti, Angelo, Barbara Frittoli, Rossella Ribolla, et al.. (2024). Early Identification of Functional High Risk Multiple Myeloma Patients after Transplant with Diffusion-Weighted Whole-Body MRI: Predictive Role of Fat Fraction in Addition to RAC Score. Blood. 144(Supplement 1). 82–82.
3.
Belotti, Angelo, Rossella Ribolla, Claudia Crippa, et al.. (2023). Predictive role of sustained imaging MRD negativity assessed by diffusion‐weighted whole‐body MRI in multiple myeloma. American Journal of Hematology. 98(9). E230–E232.
4.
Belotti, Angelo, Rossella Ribolla, Claudia Crippa, et al.. (2022). Failure to Achieve Sustained Imaging MRD Negativity Assessed By Diffusion-Weighted Whole-Body MRI (DW-MRI) Is Associated with Adverse Prognosis in Newly Diagnosed Multiple Myeloma Patients Treated with Autologous Stem Cell Transplantation Followed By Maintenance Therapy. Blood. 140(Supplement 1). 1140–1141.
5.
Belotti, Angelo, Rossella Ribolla, Marco Chiarini, et al.. (2021). Sustained Residual Disease Negativity Assessed By Diffusion-Weighted Whole-Body MRI (DW-MRI) Has Strong Predictive Relevance for Survival in Newly Diagnosed Multiple Myeloma Patients on Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT). Blood. 138(Supplement 1). 1641–1641.
6.
Belotti, Angelo, Rossella Ribolla, Valeria Cancelli, et al.. (2021). Predictive role of diffusion‐weighted whole‐body MRI (DW‐MRI) imaging response according to MY‐RADS criteria after autologous stem cell transplantation in patients with multiple myeloma and combined evaluation with MRD assessment by flow cytometry. Cancer Medicine. 10(17). 5859–5865.
7.
Belotti, Angelo, Rossella Ribolla, Valeria Cancelli, et al.. (2020). External Validation of Diffusion Weighted Whole Body MRI (DW-MRI) Response Assessment Category (RAC) Criteria Proposed By the Myeloma Response Assessment and Diagnosis System (MY-RADS) Imaging Recommendations: Prognostic Role of Imaging Response after Transplant in Multiple Myeloma and Comparison with MRD Evaluation By Flow Cytometry. Blood. 136(Supplement 1). 41–42.
8.
Belotti, Angelo, Rossella Ribolla, Valeria Cancelli, et al.. (2020). Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65‐75 years. American Journal of Hematology. 95(7). 759–765.
9.
Federico, Cinzia, Antonio Sacco, Angelo Belotti, et al.. (2019). Circulating microRNAs and Their Role in Multiple Myeloma. Non-Coding RNA. 5(2). 37–37.
10.
Gavazzoni, Mara, Enrico Vizzardi, Elio Gorga, et al.. (2018). Mechanism of cardiovascular toxicity by proteasome inhibitors: New paradigm derived from clinical and pre-clinical evidence. European Journal of Pharmacology. 828. 80–88.
11.
Belotti, Angelo, Rossella Ribolla, Valeria Cancelli, et al.. (2018). The IMWG Frailty Score and Age Can be More Effective Than Clinical Judgement in the Selection of Elderly Patients with Newly Diagnosed Multiple Myeloma Who Can Benefit from an Intensive Treatment Approach with High Dose Melphalan and Autologous Stem Cell Transplantation. Blood. 132(Supplement 1). 2151–2151.
12.
Bringhen, Sara, Stefania Oliva, Anna Marina Liberati, et al.. (2017). Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Patients: A Multicenter, Open Label Phase 1/2 Study. Clinical Lymphoma Myeloma & Leukemia. 17(1). e59–e59.
13.
Oliva, Stefania, Davine Hofste op Bruinink, Lucie Říhová, et al.. (2017). Minimal residual disease (MRD) monitoring by multiparameter flow cytometry (MFC) in newly diagnosed transplant eligible multiple myeloma (MM) patients: Results from the EMN02/HO95 phase 3 trial.. Journal of Clinical Oncology. 35(15_suppl). 8011–8011.
14.
Bringhen, Sara, Valeria Magarotto, Anna Marina Liberati, et al.. (2016). A Multicenter, Open Label Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (MM) Patients. Blood. 128(22). 1145–1145.
15.
Malagola, Michele, Cristina Skert, Erika Borlenghi, et al.. (2015). Postremission sequential monitoring of minimal residual disease by WT 1 Q‐PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk‐adapted therapy in acute myeloid leukemia patients. Cancer Medicine. 5(2). 265–274.
16.
Belotti, Angelo, Michele Malagola, Claudia Crippa, et al.. (2015). Urinary Protein Levels in Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) Predict Severe Disease Related Complications at Myeloma Progression. Blood. 126(23). 2965–2965.
17.
Malagola, Michele, Enrico Morello, Erika Borlenghi, et al.. (2014). WT1 Monitoring of Minimal Residual Disease (MRD) in Patients with Acute Myeloid Leukemia. Blood. 124(21). 3695–3695.
18.
Skert, Cristina, Manuela Fogli, Emirena Garrafa, et al.. (2014). A specific Toll‐like receptor profile on T lymphocytes and values of monocytes correlate with bacterial, fungal, and cytomegalovirus infections in the early period of allogeneic stem cell transplantation. Transplant Infectious Disease. 16(5). 697–712.
19.
Malagola, Michele, Cristina Skert, Giuseppina Ruggeri, et al.. (2014). Peripheral Blood WT1 Expression Predicts Relapse in AML Patients Undergoing Allogeneic Stem Cell Transplantation. BioMed Research International. 2014. 1–5.
20.
Turra, Alessandro, Michele Malagola, Cesare Bergonzi, et al.. (2012). Achievement of complete remission with Ponatinib therapy for Philadelphia positive acute lymphoblastic leukemia relapsed after allogeneic stem cell transplantation: a case report.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Hans‐Günter Derigs Breakdown of academic impact, for papers by Dixil Francis Breakdown of academic impact, for papers by Jennie B. Feliu Breakdown of academic impact, for papers by Katarina Uttervall Breakdown of academic impact, for papers by Maria López‐Pavía Breakdown of academic impact, for papers by Shlomzion Aumann Breakdown of academic impact, for papers by Erika Morsia Breakdown of academic impact, for papers by Kayleen Bailey Breakdown of academic impact, for papers by Adrienne Briggs Breakdown of academic impact, for papers by Lionel Adès